首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
目的 探讨利培酮合并赛来昔布对精神分裂症首发患者认知功能的影响.方法 符合美国精神障碍诊断与统计手册第4版诊断标准的精神分裂症首次发病(以下简称首发)住院患者90例,随机分到利培酮+赛来昔布组(研究组,46例)或利培酮+空白剂组(对照组,44例),观察治疗时间均为12周.认知功能评定使用阳性和阴性症状量表、汉密尔顿抑郁量表、威斯康星卡片分类(WCST)、重复性神经心理测查系统(RBANS).结果 治疗第12周末,研究组PANSS总分及分量表分低于对照组(P均<0.05);研究组HAMD评分低于对照组;两组患者RBANS测验总分及部分分量表评分均较基线明显提高,差异均有统计学意义(P均<0.05);WCST部分因子分均较基线有明显改善,差异均有统计学意义(P均<0.05);两组间各量表评分的差异均无统计学意义(P均>0.05).研究组男性患者的延时记忆量表分明显高于女性患者,差异有统计学意义(F=4.8;υ=1.0,38;P=0.03),且临床症状的改善与认知功能的提高存在显著相关性(P<0.05).结论 利培酮具有改善首发精神分裂症患者认知功能的作用;赛来昔布对男性患者的延时记忆有改善作用.  相似文献   

2.
目的 探讨利培酮与丁螺环酮分别合并帕罗西汀治疗难治性抑郁症(TRD)的疗效及社会功能的比较.方法 将91例TRD患者随机分配至帕罗西汀+利培酮组或帕罗西汀+丁螺环酮组进行双盲对照治疗8周,分别于基线、4周末、8周末评定17项汉密顿抑郁量表(HAMD -17),于基线、8周末评定社会功能缺陷筛选量表( SDSS).结果 治疗前后比较:两组治疗方案HAMD -174周末、8周末评分与基线比较以及4周末减分与8周末减分比较差异均有统计学意义(P≤0.001).SDSS 8周末评分与基线比较差异有统计学意义(P<0.001).组间比较:两组间HAMD -17评分基线、4周末、8周末、4周末减分及8周末减分比较均无统计学差异.SDSS基线、8周末评分差异无统计学意义,但SDSS 8周末减分帕罗西汀+利培酮组优于帕罗西汀+丁螺环酮组(P<0.05).结论 帕罗西汀+利培酮与帕罗西汀+丁螺环酮均能明显改善TRD的临床症状、提高社会功能,但利培酮+帕罗西汀在提高社会功能方面明显优于丁螺环酮+帕罗西汀.  相似文献   

3.
目的 研究合并代谢综合征(MS)的精神分裂症患者予吡格列酮治疗后认知功能变化.方法 40例合并MS的慢性精神分裂症患者随机分为两组,分别予吡格列酮15 mg/d(吡格列酮组)及安慰剂(安慰剂组)双盲治疗12周,在基线、12周末进行血压、体重、血糖、血脂等代谢指标评定,以及PANSS、TESS、RBANS量表评定.结果 吡咯列酮组与安慰剂组基线时高密度脂蛋白(HDL)差异有统计学意义(P<0.05),治疗12周末仅舒张压的差异有统计学意义(P<0.05);治疗12周末,吡格列酮组糖化血红蛋白、甘油三酯、HDL均优于基线时,安慰剂组HDL优于基线时,差异均有统计学意义(P<0.05).PANSS、TESS量表的评分在组内和组间比较差异均无统计学意义(P>0.05).治疗12周末,吡格列酮组视觉空间结构因子分较安慰剂组高,差异有统计学意义(P<0.05).吡格列酮组RBANS总分及即刻记忆、延迟回忆因子分较组内基线高,安慰剂组即刻记忆、延迟回忆因子分较组内基线高,差异均有统计学意义(P<0.05).结论 吡格列酮治疗合并代谢综合征的精神分裂症患者,不仅可以改善其代谢状态,而且可以改善其认知功能.  相似文献   

4.
目的 了解无抽搐电休克治疗(MECT)合并利培酮埘难治件精神分裂症(TRS)的疗效与不良反应.方法 对69例符合TRS的患者随机分为研究组34例和对照组35例,前者给予利培酮合并MECT治疗,后者单用利培酮治疗,观察12周.分别于入组前、治疗4周末、8周末和12周末时采用阳性症状和阴性症状量表(PANSS)及大体功能评定量表(GAF)评定疗效,不良反应症状量表(TESS)评定副反应.治疗前后威斯康辛卡片分类测验(WCST)评定认知功能.结果 最终纳入分析67例,研究组脱落2例.两组治疗前比较,差异无统计学意义(P>0.05);两组第4周、第8周、第12周末的PANSS总分及各因子分、GAF评分分别与自身治疗前相比,除第4周末对照组的阳性症状、阴性症状分外,差异均有统计学意义(P<0.05或P<0.01).第12周末研究组与对照组比较,PANSS总分、阳性症状、一般精神病理症状因子分的减分率、GAF评分的增加值及WCST的总测验次数、持续错误数的差异均有统计学意义(P<0.05或P<0.01);研究组PANSS减分率(45.34±15.23)%,临床总有效率56.25%,埘照组PANSSS减分率(37.14±17.19)%,临床总有效率31.43%,两组的差异有统计学意义(P<0.05).两组各时点的TESS评分差异无统计学意义(P>0.05).结论 与单一的利培酮治疗比较,利堵酬合并MECT能提高TRS的疗效,且未增加不良反应.  相似文献   

5.
目的 探索重复经颅磁刺激(rTMS)治疗对住院慢性精神分裂症患者认知功能的改善作用以及对患者血清C反应蛋白(CRP)水平的影响,初步探索rTMS影响患者认知功能的潜在机制.方法 选取2013年1月~2016年1月在天津市精神卫生中心住院治疗的精神分裂症患者60例,按照病情、性别、年龄等因素进行配对,随机分配每对患者接受rTMS真刺激治疗(治疗组)和伪刺激治疗(对照组)4周,应用阳性与阴性症状量表(PANSS)和可重复的成套神经心理状态测量(RBANS)在治疗前后评估患者的精神症状及认知功能.所有患者治疗前后均检测血清CRP水平.结果 (1)治疗后,治疗组患者的血清CRP水平明显下降,差异有统计学意义(P<0.05),而对照组无变化;(2)治疗组治疗后PANSS总分及阴性症状因子分较治疗前均有下降,差异有统计学意义(P<0.05),而对照组无变化;(3)治疗后,治疗组RBANS总分、视觉广度分、注意分、延时记忆分较前均有升高,差异有统计学意义(P<0.05),对照组RBANS总分及各因子分较治疗前差异均无统计学意义;(4)治疗组患者治疗前后PANSS总分差值与即刻记忆分差值、阴性量表分差值与RBANS总分差值及延时记忆分差值均呈负相关(P<0.05);(5)治疗组患者的血清CRP变化值与RBANS总分差值、即刻记忆、注意和延时记忆各因子差值均呈负相关(P<0.05).结论 rTMS可以有效改善慢性精神分裂症患者的认知功能,其机制可能与rTMS治疗缓解炎性反应有关.  相似文献   

6.
目的探讨吸烟对利培酮治疗首发精神分裂症的疗效和认知功能的影响。方法选择符合美国精神障碍诊断与统计手册第4版(DSM-IV)诊断标准的首发精神分裂症住院患者90例,其中吸烟患者27例,非吸烟患者63例,均使用利培酮治疗。详细收集临床资料,使用住院患者烟草使用状态调查表对患者吸烟状况进行详细调查,使用阳性和阴性症状量表(PANSS)评定基线时及治疗12周末的临床症状;威斯康星卡片分类(WCST)、重复性神经心理测查系统(RBANS)对患者在基线时及治疗12周末进行认知功能的检测,分别对吸烟组和非吸烟组的患者治疗前、后临床症状和认知功能变化值进行比较。结果基线时吸烟组患者PANSS总分(91.3±20.9)vs.(80.6±17.2)、阴性症状量表分(20.7±8.6)vs.(17.4±6.3)、一般精神病理症状量表分(43.4±12.3)vs.(38.2±10.8)均高于非吸烟组(均P〈0.05);非吸烟组的正确应答数高于吸烟组(50.6±18.2)vs.(42.2±14.3),P〈0.05,而错误应答数低于吸烟组(75.5±21.9)vs.(85.3±15.8),P〈0.05。治疗12周末,吸烟组患者阴性症状减分值为(12.2±10.4),非吸烟组(6.1±5.8)两组比较有显著性差异(t=2.7,P〈0.05);吸烟组患者WCST中完成测查总应答数、错误应答数以及学习到学会的改善值显著高于非吸烟组,差异有统计学意义(t分别为-2.2、-2.1、2.0;P均〈0.05);RBANS总分及各分量表分的增分值在两组之间差异不显著,无统计学意义(P均〉0.05)。结论吸烟患者临床症状、认知功能受损程度重于非吸烟患者;但是吸烟患者阴性症状、认知功能在治疗后的改善明显好于非吸烟患者。  相似文献   

7.
目的探讨奥氮平对精神分裂症患者认知功能的改善作用。方法使用新韦氏记忆量表(WMSRC)、威斯康星卡片分类测验(WCST)、阳性症状与阴性症状量表(PANSS)、标准化的精神分裂症认知功能成套测验(MCCB)对患者的认知功能进行综合评定。结果治疗8周后,患者的记忆商数较治疗前有显著提高(P0.05);患者总测试次数、随机错误数、持续错误数均显著性下降(P0.05);但分类完成数、正确数无显著性变化(P0.05);患者治疗前后语言记忆及数字序列间存在显著差异(P0.01);治疗前后其迷宫、视觉记忆、空间广度及持续操作测试结果存在显著差异(P0.05),治疗前后患者连线及情绪管理检测结果差异无统计学意义(P0.05);阴性及阳性症状减分值、PANSS总分减分值与患者记忆商数增加值间呈显著正相关关系(P0.05或P0.01);患者PANSS总分减分值和一般病理性症状减分值与随机错误数减分值及阳性/阴性症状减分值与持续错误数减分值间均存在显著正相关关系(P0.05);治疗期间均未出现严重的不良反应。结论奥氮平可以显著改善精神分裂症患者的认知功能障碍,值得临床推广应用。  相似文献   

8.
目的探讨吸烟与非吸烟首发精神分裂症患者临床症状、认知功能与BDNF的相关性。方法符合美国精神障碍诊断与统计手册第四版(DSM-Ⅳ)诊断标准的首发精神分裂症住院患者81例,其中吸烟27例,非吸烟54例。采用阳性和阴性症状量表(PANSS)、威斯康星卡片分类(WCST)、重复性神经心理测查系统(RBANS)评估精神症状和认知功能,采用酶联免疫吸附法检测血清BDNF水平。结果吸烟组PANSS总分、阴性症状分、一般精神病理症状分均高于非吸烟组(t=2.5,2.0,2.0,P均0.05),吸烟组的正确应答数显著高于非吸烟组,吸烟组错误应答数显著低于非吸烟组(t=2.02,-2.26,P均0.05)。吸烟组患者血清BDNF水平为(8.8±4.6)μg/L,非吸烟组为(9.2±4.3)μg/L,两组比较差异不显著,无统计学意义(t=0.38,υ=83,P0.05);吸烟患者BDNF与患者总病程、PANSS总分、一般精神病理症状分呈显著正相关(r=0.66,0.54,0.54,P均0.05);与RBANS词汇回忆、故事回忆、图形回忆、编码测验分值、延时记忆因子呈显著负相关(r=-0.48,-0.45,-0.45,-0.53,P均≤0.05);非吸烟患者BDNF与PANSS中阳性症状分呈显著正相关(r=0.27,P0.05)。结论吸烟精神分裂症患者BDNF水平与精神症状可能存在相关性。  相似文献   

9.
目的探讨阿立哌唑与利培酮对首发未用药精神分裂症患者疗效、认知功能及血清脑源性神经营养因子(BDNF)浓度的影响。方法 83例患者随机分为阿立哌唑组(43例)和利培酮组(40例),疗程8周。用阳性和阴性症状量表(PANSS)、精神分裂症认知功能成套测验(MCCB)、副反应量表(TESS)评定临床疗效、认知功能及副反应,用酶联免疫吸附法(ELISA)检测血清BDNF浓度。结果治疗8周后,1两组有效率、副反应发生率差异均无统计学意义(P0.05);2阿立哌唑组在MCCB中符号编码、语义流畅性、言语记忆、空间广度、数字序列、迷宫、视觉记忆及总分上明显高于利培酮组(P0.05);3阿立哌唑组血清BDNF浓度明显高于利培酮组(P0.01)。结论阿立哌唑治疗精神分裂症的总体疗效与利培酮相当;但在改善认知功能、升高血清BDNF浓度优于利培酮。  相似文献   

10.
目的 探讨丙戊酸钠改善精神分裂症患者认知功能障碍的疗效.方法 将80例精神分裂症患者随机分成研究组(40例)和对照组(40例),研究组患者使用新型抗精神病药合并丙戊酸钠系统治疗,对照组患者单用新型抗精神病药物系统治疗,共治疗8周.全部病例在治疗前后分别进行阳性和阴性综合征量表(PANSS)、韦氏成人智力量表(WAIS-RC)、韦氏记忆量表(WMS)、威斯康星卡片分类测验(WCST)进行疗效评定,应用治疗中需处理的不良反应症状量表(TESS)评定不良反应.结果 与基线时比较,两组在治疗后第4、8周末PANSS总分及各因子分均有明显降低(P<0.05),研究组治疗后第8周末PANSS总分及各因子分均显著低于对照组(P<0.05).治疗后第8周末,两组WMS、WAIS-RC、WCST评分与基线时比较,除即刻记忆评分外其余各项评分差异均有统计学意义(P<0.05),两组间比较,除即刻记忆评分外其余各项评分均有显著性差异(P <0.05,P<0.01).结论 丙戊酸钠对精神分裂症患者的认知功能障碍有明显改善效果.  相似文献   

11.

Background

Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal plasticity. The aim of the present study was to measure serum BDNF levels in depression and to analyze the relationship between BDNF levels and severity of depression.

Methods

Thirty patients meeting the DSM-IV criteria for major depressive disorder and 40 normal control subjects were recruited for this study. Patients had not used psychotropic drugs. The severity of depression was assessed by the Hamilton Rating of Depression Scale (HAM-D). Serum BDNF levels were determined by using ELISA.

Results

HAM-D scores were 17.09 ± 4.96 in depressed patients. We determined that the serum BDNF levels of the depression patients were lower than those of the healthy control group (respectively, 1453.42 ± 144.51 pg/ml, 1632.23 ± 252.93 pg/ml, t = 3.467, p = 0.001, independent t test). No correlation was found between the patients’ serum BDNF levels and HAM-D scores (p > 0.05, Pearson correlation analysis).

Conclusions

Our results suggest that serum BDNF levels are low in depression. However it was not found association between serum BDNF levels and the severity of depression.  相似文献   

12.
Preclinical study results suggest that brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) modulate addictive behaviour. Therefore we investigated alterations in BDNF (81 male patients) and GDNF serum levels (52 male patients) in alcohol-dependent patients during alcohol withdrawal (day 1, 7 and 14) in comparison to healthy controls (41 male controls).  相似文献   

13.
The role of brain-derived neurotrophic factor (BDNF) is to promote and modulate the neuronal responses across neurotransmitter systems in the brain. Therefore, abnormal BDNF signaling may be associated with the pathophysiology of schizophrenia. Decreased BDNF levels in the brain and the serum of patients with psychotic disorders have been reported. In the present study, we assessed serum BDNF levels in a group of 14 drug-naive first-episode patients with schizophrenia (FEP), compared to 15 healthy controls. The serum BDNF levels in the sample of FEP patients was significantly reduced compared to normal controls (23.92+/-5.99 ng/ml vs. 30.0+/-8.43 ng/ml, F=5.01, df=1, p=.034). Negative correlations were shown between serum BDNF levels of the patients and the PANSS Positive and Negative subscale scores. Our findings indicate that BDNF levels at the onset of schizophrenia may reflect associated pathophysiological processes as well as the severity of positive and negative psychotic symptoms.  相似文献   

14.
Brain-derived neurotrophic factor (BDNF) is active during a critical developmental period and likely influences the neuroplasticity of schizophrenia. This study longitudinally examined the effects of atypical antipsychotics on serum BDNF levels in schizophrenic patients. Specifically, this study measured serum BDNF levels in 53 patients with paranoid schizophrenia during a relapse and again 4 weeks following the administration of antipsychotic treatment (with risperidone in 32 cases, and clozapine in 21 cases). BDNF levels remained unchanged relative to study entry after 4 weeks of atypical antipsychotic treatment. However, serum BDNF was significantly increased in the subgroup receiving risperidone compared to that receiving clozapine, albeit only in the 15 male subjects and not in the 17 females. These results suggest that gender might significantly influence the antipsychotic treatment of schizophrenia from the perspective of BDNF. These findings may also indicate that the treatment with atypical antipsychotic agents differentially affects BDNF levels.  相似文献   

15.

Objective

To determine the effect of BDNF gene val66met polymorphism on serum BDNF levels in drug-free patients with major depressive disorder (MDD) and healthy subjects, that differ by gender.

Methods

Sixty-six drug-free patients (19 males + 47 females) with non-psychotic MDD and fifty-six healthy controls (18 males + 38 females) were recruited. Three-way ANOVA was employed to analyze the effect of mental health status, met-carriage and gender on Hamilton Depression Rating Scale (HDRS) scores and serum BDNF levels, by using the MIXED Procedure (SAS).

Results

Patients had a lower serum BDNF level than healthy subjects (22.47 vs. 27.49; p < 0.0001). Met-carrier patients had a higher HDRS score than Val homozygote's (25.99 vs. 22.99, p < 0.02). Serum BDNF level for met-carrier subjects (patients + controls) was lower than Val homozygote subjects (23.08 vs. 26.87; p < 0.002). However, there were no effects of two-way interactions of met-carriage and mental health status on HDRS scores and serum BDNF levels. There was no gender effect on HDRS scores in the patients. Overall, male subjects (patients + controls) had a higher serum BDNF level than female subjects (26.87 vs. 23.08; p < 0.002). However, there were no effects of two-way interactions of gender with mental health status and met-carriage on serum BDNF levels.

Conclusions

We replicated the previous findings of lower serum BDNF levels during depression and in females. In addition, we found that met-carriage had an effect in reducing serum BDNF levels, regardless of gender and depression. Further animal and human studies with a larger sample size should investigate whether BDNF val66met polymorphism could alter brain and serum BDNF levels.  相似文献   

16.
17.
18.
目的 探讨抑郁症患者血清脑源性神经营养因子水平及其相关因素,为防治抑郁症提供重要依据.方法 采用酶联免疫吸附法和汉密尔顿抑郁量表分别测定40例抑郁症患者(患者组)的血清BDNF水平和抑郁严重程度,并与49名正常者(对照组)进行对比分析.结果 患者组治疗前血清BDNF水平明显降低,与对照组比较差异有统计学意义(P<0.01).患者组治疗8周末血清BDNF水平明显升高,HAMD总分明显降低,与治疗前比较差异有统计学意义(P<0.05).患者组治疗前后血清BDNF水平与性别及年龄均呈负相关,差异具有统计学意义(P<0.05),与受教育程度、病程及HAMD总分比较无统计学意义(P>0.05).结论 抑郁症患者存在血清BDNF水平的下降,抗抑郁治疗可改善抑郁症状,并显著提高血清BDNF水平.  相似文献   

19.
20.
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome characterized by psychological and somatic symptoms commencing in the luteal phase of the menstrual cycle and concludes with menstrual bleeding. PMDD affects 3–8 % of premenopausal women and represents a significant public health problem especially in young women. Decreased brain-derived neurotrophic factor (BDNF) levels are associated with several mental disorders. Heat-shock protein-70 (HSP70) is an important member of the molecular chaperone system, which provides a molecular defense against proteotoxic stress. We hypothesized that there would be changed levels of BDNF and HSP70 in women with PMDD compared with non-symptomatic women, reflecting impaired and/or activated stress-related responses involved in the underlying pathogenesis of PMDD. Female medical students were screened, and 24 women without premenstrual symptoms and 25 women with PMDD were enrolled in the study. Psychiatric evaluation and the Daily Record of Severity of Problems-Short Form were used for two consecutive menstrual cycles to diagnose PMDD. Serum BDNF and HSP70 levels were assessed in the third luteal phase. Participants with PMDD had significantly higher serum BDNF and HSP70 levels compared with controls, and there was a significant positive correlation between serum BDNF and HSP70 levels. Increased HSP70 levels may reflect cellular distress in PMDD. Increased serum BDNF levels in the luteal phase in subjects with PMDD may reflect a compensation process, which results in subsequent improvement of PMDD-associated depressive symptoms in the follicular phase. Thus, increased serum BDNF levels may be indicative of a compensating capacity in PMDD.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号